Clinical and experimental studies of cancer. We are running a randomized clinical trial on local treatment of breast cancer liver metastases and participate in several trials in national and international collaborations.
In our lab, we study the MAPK signaling pathway and develop a model i C. elegans to identify novel treatments of cancer.
Cancer progression is often driven by oncogenic mutations in the MAPK signalling pathway. Our group studies BRAF- and KRAS-activated cancer to explore targets to circumvent drug resistance and to find novel treatments. Currently, we focus on the tumour suppressor LRIG1 in relation to BRAF inhibitor resistance in malignant melanoma.